Molluscum contagiosum

Novan’s Phase 2 SB206 Molluscum Study Published in Journal of the American Academy of Dermatology

Retrieved on: 
Tuesday, October 8, 2019
Molluscum contagiosum, Poxviruses, RTT

In this Phase 2 study, SB206 demonstrated clinical efficacy with a favorable safety profile.

Key Points: 
  • In this Phase 2 study, SB206 demonstrated clinical efficacy with a favorable safety profile.
  • The publication of this Phase 2 study through a prestigious platform such as JAAD underscores Novans innovative nitric-oxide technology and provides exposure to the results that supported our decision to progress into a Phase 3 molluscum program.
  • Dr. Maeda-Chubachi further commented, We look forward to reporting out the results from our Phase 3 B-SIMPLE pivotal program in the near future.
  • Title: Efficacy and Tolerability of an Investigational Nitric Oxide-releasing Topical Gel in Patients With Molluscum Contagiosum: A Randomized Clinical Trial
    Publication: Journal of the American Academy of Dermatology (Available online 03 October 2019), doi: https://doi.org/10.1016/j.jaad.2019.09.064.

Verrica Pharmaceuticals Submits New Drug Application to U.S. Food and Drug Administration for VP-102 for the Treatment of Molluscum Contagiosum

Retrieved on: 
Monday, September 16, 2019
RTT, Viruses, Infectious diseases, Molluscum contagiosum, Poxviruses, Medical specialties, Wart

Without treatment, molluscum can persist for an average of 13 months, with some cases remaining unresolved for several years.

Key Points: 
  • Without treatment, molluscum can persist for an average of 13 months, with some cases remaining unresolved for several years.
  • The CAMP-1 and CAMP-2 studies enrolled 528 patients in total and were conducted at 31 centers in the United States.
  • The companys late-stage product candidate, VP-102, is a potential first-in-class topical therapy for the treatment of molluscum contagiosum and common warts.
  • Following positive topline results from two pivotal Phase 3 trials, the company submitted a NDA for VP-102 for the treatment of molluscum.

Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright 21st Annual Global Investment Conference

Retrieved on: 
Wednesday, August 28, 2019
RTT, Viruses, Infectious diseases, Microbiology, Molluscum contagiosum, Genital wart, Wart, Dermatology, Plantar wart, Imiquimod

Verrica is a medical dermatology company committed to the development and commercialization of novel treatments that provide meaningful benefit for people living with skin diseases.

Key Points: 
  • Verrica is a medical dermatology company committed to the development and commercialization of novel treatments that provide meaningful benefit for people living with skin diseases.
  • The companys late-stage product candidate, VP-102, is a potential first-in-class topical therapy for the treatment of molluscum contagiosum and common warts.
  • Verrica is planning to meet with the FDA to determine next steps on the development of VP-102 for common warts following positive Phase 2 results.
  • VP-102 is also currently in a Phase 2 trial for the treatment of external genital warts.

Novan’s Phase 3 Molluscum Pivotal Program Completes Enrollment

Retrieved on: 
Tuesday, August 13, 2019
Molluscum contagiosum, Poxviruses, RTT

The SB206 results from Phase 2, previously announced in December 2018, demonstrated a clear treatment effect on the complete clearance of all molluscum lesions at Week 12 for 12% once-daily SB206 gel.

Key Points: 
  • The SB206 results from Phase 2, previously announced in December 2018, demonstrated a clear treatment effect on the complete clearance of all molluscum lesions at Week 12 for 12% once-daily SB206 gel.
  • There were signs of efficacy as early as Week 2, and the Phase 2 trial showed a favorable safety profile.
  • Dr. Messersmith further commented, The Novan team, along with the investigators and program coordinators, have done an exceptional job in achieving this important milestone.
  • The B-SIMPLE Phase 3 program consists of two multi-center, randomized, double-blind, vehicle-controlled studies, B-SIMPLE1 and B-SIMPLE2, to evaluate the efficacy and safety of SB206 12% once daily for the treatment of molluscum.

Ligand Acquires Milestone and Royalty Rights to SB206 from Novan, Inc.

Retrieved on: 
Monday, May 6, 2019
Health, Biotechnology, Infectious diseases, Pharmaceutical, Other Health, General Health, Branches of biology, Natural sciences, Health, Molluscum contagiosum, Poxviruses, RTT, Ligand Pharmaceuticals, Medication, Food and Drug Administration, Ligand, Antiviral drug

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the acquisition of economic rights to SB206 from Novan, Inc. SB206 is a Phase 3 topical antiviral gel for the treatment of skin infections, including molluscum contagiosum.

Key Points: 
  • Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the acquisition of economic rights to SB206 from Novan, Inc. SB206 is a Phase 3 topical antiviral gel for the treatment of skin infections, including molluscum contagiosum.
  • The drug candidate targets a condition mostly affecting children and with a significant unmet medical need, said John Higgins, Chief Executive Officer of Ligand.
  • There are currently no therapies approved by the U.S. Food and Drug Administration (FDA) for the treatment of molluscum.
  • Ligand disclaims any intent or obligation to update these forward-looking statements beyond the date of this report.

InventHelp Inventor and Pharmacist Develops an Enhanced Means to Treat Molluscum (SVH-167)

Retrieved on: 
Wednesday, December 5, 2018
RTT, Molluscum contagiosum, Microbiology, Wart, Medicine, Tree of life biology)

Dr. Duran, Pharm.D., developed the PHARM D CREAM which she believed would treat highly contagious Molluscum.

Key Points: 
  • Dr. Duran, Pharm.D., developed the PHARM D CREAM which she believed would treat highly contagious Molluscum.
  • This over-the-counter cream may help eliminate the lesions/warts within two to three weeks of use.
  • It provides an alternative to traditional treatments which may require a prescription and can cause skin irritation and burning/stinging.
  • 17-SVH-167, InventHelp, 217 Ninth Street, Pittsburgh, PA 15222, or call (412) 288-1300 ext.